The Bang For Celgene’s Buck: Looking Inside The Record-Setting Juno Deal
Executive Summary
Celgene’s $1 billion collaboration with Juno was the highest ever upfront payment for a biopharma licensing deal. Execs broke down the deal specifics in an interview with “The Pink Sheet.”
You may also be interested in...
Regeneron And Bluebird Team Up In Cell Therapy "Joint Venture"-Style Deal
Regeneron will make a $100m equity investment in bluebird to collaborate on the discovery of antibodies and T cell receptors, with the hope of building out in immuno-oncology and overcoming some of the early cell therapy challenges. Regeneron's business development chief talks to Scrip about its strategy.
Bristol Goes In Big On New Valentine Nektar
Bristol paid a handsome $1.85bn upfront for access to Nektar's lead immuno-oncology program NKTR-214 to study in combination with its own drugs, but the expense was viewed by some as a smart play versus buying Nektar outright.
Bluebird Flies On 100% Response Rate For Anti-BCMA CAR-T
Data from a Phase I trial testing the CAR-T therapy bb2121 in in heavily treated patients with relapsed refractory multiple myeloma were encouraging, driving bluebird's stock up 10%.